Athira Historical Financial Ratios
| ATHA Stock | USD 0.34 0.01 3.03% |
Athira Pharma is presently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.53 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Athira Pharma financial condition quickly.
Athira |
About Athira Financial Ratios Analysis
Athira PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Athira Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Athira financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Athira Pharma history.
Athira Pharma Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Athira Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Athira Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.At present, Athira Pharma's PTB Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 1.22, whereas Free Cash Flow Yield is forecasted to decline to (4.52).
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 9.68 | 5.37 | 4.18 | 3.97 | Net Debt To EBITDA | 0.99 | 0.76 | 0.47 | 0.44 |
Athira Pharma fundamentals Correlations
Click cells to compare fundamentals
Athira Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Athira Pharma fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 4.06 | 1.5 | 0.51 | 0.71 | 0.5 | 0.53 | |
| Book Value Per Share | 8.44 | 8.7 | 6.23 | 3.42 | 1.17 | 1.22 | |
| Free Cash Flow Yield | (0.0238) | (0.0929) | (0.62) | (1.09) | (4.31) | (4.52) | |
| Operating Cash Flow Per Share | (0.11) | (0.74) | (1.17) | (1.92) | (2.65) | (2.53) | |
| Pb Ratio | 4.06 | 1.5 | 0.51 | 0.71 | 0.5 | 0.53 | |
| Free Cash Flow Per Share | (0.81) | (1.21) | (1.95) | (2.66) | (2.53) | (2.65) | |
| Roic | (0.0678) | (0.2) | (0.4) | (0.95) | (2.19) | (2.3) | |
| Net Income Per Share | (0.57) | (1.47) | (2.31) | (3.09) | (2.52) | (2.65) | |
| Cash Per Share | 5.69 | 6.87 | 5.31 | 3.88 | 1.33 | 1.27 | |
| Pocfratio | (46.14) | (11.16) | (1.65) | (0.92) | (0.23) | (0.24) | |
| Interest Coverage | (15.75) | (54.48) | (21.3K) | (4.28) | (4.92) | (5.17) | |
| Pfcf Ratio | (42.09) | (10.77) | (1.62) | (0.91) | (0.23) | (0.24) | |
| Income Quality | 1.21 | 0.79 | 0.76 | 0.86 | 1.0 | 0.71 | |
| Roe | (0.0679) | (0.17) | (0.37) | (0.9) | (2.16) | (2.05) | |
| Ev To Operating Cash Flow | (43.67) | (8.64) | (0.35) | (0.0336) | 0.25 | 0.27 | |
| Pe Ratio | (59.71) | (8.85) | (1.37) | (0.79) | (0.23) | (0.24) | |
| Return On Tangible Assets | (0.0667) | (0.16) | (0.34) | (0.73) | (1.65) | (1.57) | |
| Ev To Free Cash Flow | (39.84) | (8.34) | (0.35) | (0.0335) | 0.25 | 0.27 | |
| Earnings Yield | (0.0167) | (0.11) | (0.73) | (1.27) | (4.29) | (4.51) | |
| Net Debt To E B I T D A | 3.14 | 2.0 | 0.99 | 0.76 | 0.47 | 0.44 | |
| Current Ratio | 43.66 | 28.07 | 9.68 | 5.37 | 4.18 | 3.97 | |
| Tangible Book Value Per Share | 8.44 | 8.7 | 6.23 | 3.42 | 1.17 | 1.22 | |
| Shareholders Equity Per Share | 8.44 | 8.7 | 6.23 | 3.42 | 1.17 | 1.22 | |
| Debt To Equity | 0.003646 | 0.00598 | 0.008127 | 0.0122 | 0.0271 | 0.0285 | |
| Graham Net Net | 5.53 | 6.59 | 4.71 | 3.12 | 0.97 | 1.02 | |
| Interest Debt Per Share | 0.0421 | 0.0521 | 0.7 | 0.0417 | 0.0316 | 0.03 | |
| Debt To Assets | 0.003577 | 0.005783 | 0.007403 | 0.009891 | 0.0207 | 0.0197 | |
| Enterprise Value Over E B I T D A | (55.39) | (6.85) | (0.27) | (0.029) | 0.24 | 0.26 | |
| Price Earnings Ratio | (59.71) | (8.85) | (1.37) | (0.79) | (0.23) | (0.24) | |
| Price Book Value Ratio | 4.06 | 1.5 | 0.51 | 0.71 | 0.5 | 0.53 | |
| Price Earnings To Growth Ratio | (0.19) | (0.056) | (0.024) | (0.0233) | 0.0126 | 0.012 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.